Research programme: PARP inhibitors - AstraZeneca
Alternative Names: AZ 108; AZ 482; PARP 6 inhibitors - AstraZenecaLatest Information Update: 28 Jul 2018
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in USA
- 20 Oct 2013 Preclinical trials in Cancer in USA (unspecified route)